GERN Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges GERN Investors with Losses to Contact the Firm

Core Viewpoint - Securities class action lawsuits have been filed against Geron Corporation for allegedly misleading investors regarding its revenue outlook and product performance during the specified class period [1][3]. Group 1: Allegations Against Geron Corporation - Defendants allegedly created a false impression of reliable information regarding Geron's revenue outlook and growth potential while downplaying risks from seasonality and macroeconomic factors [3]. - Reports on the launch success and growth potential of Geron's primary product, RYTELO, were claimed to be overly optimistic and did not reflect the reality of market conditions, competition, and patient initiation challenges [3]. - RYTELO reportedly lacked market penetration awareness, hindering Geron's ability to meet the significant unmet need for the drug, especially among first-line patients [3]. - Statements made by the defendants regarding the company's business and prospects were claimed to be materially false and misleading [3]. Group 2: Legal Process for Investors - Geron investors can seek to be appointed as lead plaintiffs by May 12, 2025, through Kessler Topaz Meltzer & Check, LLP or other counsel [4]. - A lead plaintiff represents the interests of all class members and typically has the largest financial stake in the case [4]. - Investors who choose not to serve as lead plaintiffs can still participate in any recovery as absent class members [4].